PMID- 22961097 OWN - NLM STAT- MEDLINE DCOM- 20140522 LR - 20181202 IS - 1439-0795 (Electronic) IS - 0176-3679 (Linking) VI - 46 IP - 2 DP - 2013 Mar TI - Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. PG - 54-8 LID - 10.1055/s-0032-1321908 [doi] AB - INTRODUCTION: Depression, stress and antidepressant treatment have been found to modulate the expression of brain-derived neurotrophic factor (BDNF). Recent research suggests that serum BDNF concentration is reduced in depression and that antidepressant treatment leads to an increase in serum BDNF concentration. METHODS: We studied depressed patients receiving a randomized antidepressant treatment with either mirtazapine (n=29) or venlafaxine (n=27) for 28 days in a prospective design. Changes in the concentrations of serum neurotrophins in response to antidepressant treatment were assessed. RESULTS: There was a significant "treatment" by "medication" interaction effect on BDNF serum concentrations that indicated a decline of BDNF in venlafaxine-treated patients (7.82+/-3.75-7.18+/-5.64 ng/mL), while there was an increase in mirtazapine-treated patients (7.64+/-6.23-8.50+/-5.37 ng/mL). There was a trend for a "treatment" by "remission" interaction with a favourable clinical course being related to increasing serum BDNF. DISCUSSION: Changes in BDNF serum concentrations as a result of antidepressant therapy depend on the antidepressant and potentially on the clinical course. CI - (c) Georg Thieme Verlag KG Stuttgart . New York. FAU - Deuschle, M AU - Deuschle M AD - Faculty of Medicine Mannheim, Central Institute of Mental Health, University of Heidelberg, Germany. michael.deuschle@zimannheim.de FAU - Gilles, M AU - Gilles M FAU - Scharnholz, B AU - Scharnholz B FAU - Lederbogen, F AU - Lederbogen F FAU - Lang, U E AU - Lang UE FAU - Hellweg, R AU - Hellweg R LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20120907 PL - Germany TA - Pharmacopsychiatry JT - Pharmacopsychiatry JID - 8402938 RN - 0 (Antidepressive Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Cyclohexanols) RN - 250PJI13LM (Mianserin) RN - 7D7RX5A8MO (Venlafaxine Hydrochloride) RN - A051Q2099Q (Mirtazapine) SB - IM MH - Antidepressive Agents/*pharmacology/therapeutic use MH - Brain-Derived Neurotrophic Factor/*blood MH - Cyclohexanols/pharmacology/*therapeutic use MH - Depressive Disorder, Major/*blood/*drug therapy MH - Female MH - Humans MH - Male MH - Mianserin/*analogs & derivatives/pharmacology/therapeutic use MH - Middle Aged MH - Mirtazapine MH - Treatment Outcome MH - Venlafaxine Hydrochloride EDAT- 2012/09/11 06:00 MHDA- 2014/05/23 06:00 CRDT- 2012/09/11 06:00 PHST- 2012/09/11 06:00 [entrez] PHST- 2012/09/11 06:00 [pubmed] PHST- 2014/05/23 06:00 [medline] AID - 10.1055/s-0032-1321908 [doi] PST - ppublish SO - Pharmacopsychiatry. 2013 Mar;46(2):54-8. doi: 10.1055/s-0032-1321908. Epub 2012 Sep 7.